The potential threat of a large outbreak of variant Creutzfeldt-Jakob disease initiated a proliferation of research into the understanding and treatment of human prion disease. However, clinical research is at an early stage with a pressing need for objective evaluation of treatments to inform the design of future studies.
The furor over bovine spongiform encephalopathy (BSE) and potential threat of an epidemic of variant Creutzfeldt-Jakob disease (vCJD) has prompted increased research into the understanding and treatment of prion disease. These neurodegenerative conditions are progressive, fatal, and currently incurable. Sporadic Creutzfeldt-Jakob disease (sCJD) accounts for around 80 -85% of cases, [1] [2] [3] [4] occurs worldwide, and although of unknown cause is thought to arise through spontaneous change to prion proteins in the brain, or by somatic mutation in the prion protein gene (PRNP). It usually affects people in middle to old age and is typically characterized by rapidly progressive dementia, associated with other neurologic features (frequently ataxia and myoclonus) leading to death in a few months. Inherited prion disease (iPD) accounts for about 10 -15% of cases [1] [2] [3] [4] and occurs as a result of inherited mutations in the gene coding for prion protein. Inherited prion diseases have previously been classified clinicopathologically as familial CJD, Gerstmann-Straussler-Scheinker syndrome, and fatal familial insomnia. These are now more specifically defined according to the differing underlying genetic mutations. These mutations give rise to considerable variability in the manifestation of disease but there can also be clinical variability within families with the same mutation. Acquired disease accounts for around 1 to 5% of cases, [3] [4] [5] from Ͻ1% in Germany 5 to 5% in the UK (www.cjd.ed.ac.uk) depending on the prevalence of specific acquired forms. Infection occurs either by transmission during medical or surgical procedures leading to iatrogenic CJD (iCJD), or by dietary exposure. Historically, Kuru, prevalent in the Fore group of Papua New Guinea, was acquired as a result of cannibalistic ingestion of brain tissue. Recently, ingestion of material from BSE infected cattle has been implicated in the emergence of vCJD, first described in the United Kingdom in 1996. 6 Patients with vCJD tend to be younger than sporadic cases and initial symptoms are often behavioral or psychiatric rather than specifically neurologic. 7 In vitro and animal model studies have suggested a number of categories of drugs as candidates for treatment, 8 but formal clinical studies are at an early stage. This systematic review was therefore initiated to establish an evidence base on which therapeutic studies can build. It complements the systematic review of laboratory studies published recently, 9 which also provides more detailed information on the pathogenesis of prion disease. Most high quality systematic reviews of treatment in healthcare consider only the most reliable evidence, usually from randomized controlled trials. 10 However, given the known lack of formal evaluation of drug effectiveness, we aimed to consider any clinical study of the treatment of prion disease in humans and, to establish baselines against which to informally compare treatment studies, we also sought evidence on disease progression from published patient series.
METHODS Methods were prespecified in a protocol which is available online (appendix e-1 on the Neurology ® Web site at www.neurology.org). We aimed to include any published report of well-defined groups of untreated patients (prospective and retrospective studies and case control studies in a given setting or within a specific time frame and based on direct observation or information from clinical notes). We also aimed to include any clinical study of the treatment of human prion disease. Diagnostic studies were considered outside the scope of this review, as were in vitro or animal model studies, which are the subject of a separate systematic review. 9 Experimental studies measuring only immediate response to drugs such as those observed during EEG assessment were also excluded.
Medline was initially searched from 1966 to 2005 and this search was updated in 2007 with respect to treatment studies. No restriction was placed on the language of publication. Owing to the diversity of study types being considered and because well-defined search strategies are available only for controlled trials, the search was designed to be as broad as possible (search strategy available on request), accepting that it would yield a high number of irrelevant citations. We also searched the following conference proceedings: New perspectives for prion therapeutics, 2002; Prion disease: from basic research to intervention concepts, 2003; Neuroprion 2004 -2006. Bibliographies of all eligible studies were checked for references to further studies. We additionally cross-checked the references from a random sample of 20 review articles to assess whether it was necessary to extend this to the several hundred such articles identified via Medline. The following trial registers were searched for any ongoing or completed studies: ClinicalTrials.gov, metaRegister of Controlled Trials, Centerwatch, and the Cochrane Central Controlled Trials Register.
Two individuals independently screened downloaded Medline abstracts for eligibility, and resolved discrepancies by consensus and by obtaining the full article for studies where eligibility was uncertain. Full articles were obtained for all abstracts that appeared to describe a well-defined group of patients. All those that suggested the use of an intervention were also obtained. These articles were read and appraised for eligibility. Reasons for ineligibility were noted for those studies excluded at this stage and a list of these is available in appendix e-2. Data were extracted from reports of eligible studies by one individual onto standard forms and checked by a second individual. Any ambiguities or discrepancies were resolved by discussion, involving a third individual if necessary. Disease stage at the time of treatment was categorized broadly, based on mobility and ability to function independently (staging criteria are available in appendix e-3). For articles published in languages other than English, data were abstracted from the English summary and from translation of pertinent parts of articles published in Chinese, French, German, Hungarian, Italian, Japanese, Polish, Portuguese, Russian, and Spanish.
In many reports the description of untreated patient series was unclear. Our protocol stated that to be included patients had to have been selected using objective criteria (for example, all patients diagnosed in a particular hospital during a specified period) or based on established families in inherited disease, rather than ad hoc assemblages of patients. However, a considerable number of reports did not present sufficient information to enable us to apply these criteria, and we suspected that many would not meet them. We decided, however, to be inclusive, and have noted the cohort definition (or lack of) in tables of untreated patient series which are available in tables e-1 to e-5.
Where several articles reported the same group of patients, we tabulated data extracted from the most recent article, supplemented with additional information from previous reports where necessary, noting prior or duplicate reports in the tables. In inherited disease, where information on families was dispersed among articles, patients were matched across publications and then the best available information on each patient was extracted. These data were then collated and included in the data tables to use the maximal (unduplicated) information across studies. Wherever possible, data were tabulated only for definite (neuropathologically confirmed according to the techniques and criteria accepted at the time) and probable cases (as reported in each individual paper). We did not attempt to reclassify probable cases according to current internationally accepted diagnostic criteria 11 as articles did not present sufficient information to allow this.
RESULTS
A total of 400 potentially eligible publications were identified (311 from 3,263 citations returned by Medline searches, 89 from other searches). We were unable to locate three articles and 107 studies were ineligible according to prespecified criteria. Reasons for ineligibility included treatment studies that measured only immediate effects; animal studies of treatment; case reports from single untreated individuals; studies that did not report the quantitative data required for the review, including those that were primarily studies of genetics, incidence, or risk; review articles; or news and comment. As reviewing the 1,512 citations included in the bibliographies of 20 randomly selected relevant review articles did not identify any eligible study that had not been already identified by other means, we concluded that it was not resource-effective to cross-check the bibliographies of further review articles. The update of the Medline search in 2007 yielded four publications that were eligible to be included in the treatment part of the review. Peer reviewers brought to our attention two additional articles that had been published subsequent to our journal submission. As these concerned treatment with pentosan polysulfate, they were also included. Altogether, 173 articles were eligible for inclusion and a further 123 articles were found to be previous or alternative publications of these same studies.
Studies of untreated patient series. Tables e-1 to e-5
give full details of the individual 140 published patient series included in the review, with information from 32 countries and over 9,000 patients. Information on age at onset and duration of disease are summarized in table e-6. As single cases of untreated individuals did not meet our pre-specified inclusion criteria we note that reports of published individual cases of additional PRNP mutations, which were identified by our literature searches, are excluded. This is also true of published notification of new single cases of vCJD reported outside of the United Kingdom and France (Canada, Ireland, Italy, Japan, Portugal, Saudi Arabia, Spain, The Netherlands, and United States). Table e-6 shows a wide variation among studies. For sporadic disease, the median of reported average time from onset of symptoms to death was 6 months (range for individual patients 1 month to 11 years). Variant CJD had a median duration of 14 months (range 1 month to 39 months). For iatrogenic disease acquired from growth hormones the median was 9 months (range 2 to 30 months) and acquired from transplanted dura mater (membrane surrounding the brain or spine) the median was 7 months (range 3 to 33 months). For inherited prion disease the median was 14 months (range 1 month to 23 years).
Studies of treated patients. The table and table e-7 provide summary details of the 33 articles published between 1971 and 2007 reporting clinical information from 149 treated patients.
Fourteen different interventions (analgesic, anticoagulant, anticonvulsant, antidepressant, antifungal, antimalarial, and antiviral drugs, together with antioxidants/vitamins and biologic response modifiers) have been used with therapeutic intent, both to try to slow or alter disease progression and to alleviate symptoms. A brief summary of the reported effects of each is given below. Antiviral drugs. Acyclovir. Two reports 12,13 each describe treatment of a single unspecified CJD patient with acyclovir given at 30 mg/kg/day and 1,500 mg/day. Neither reported any change in the patients' condition. Survival information is given for one individual who died 4 weeks after treatment with a disease duration of 10 months. 12 Toxicity was stated as none in one report 12 and was not commented on in the other. 13 Two other patients were mentioned briefly in reports of untreated patient series as having been given acyclovir without benefit, but no further details were given. 14, 15 Amantadine. Two comparative studies 16, 17 comprising 17 patients with CJD and 6 case reports 18-23 of a total of seven patients with CJD were published between 1971 and 1984. Neither comparative study provides details of how patients were selected. One, 16 in which two of four control group patients also received short-term amantadine, reported no change in clinical symptoms and no difference in survival. Median sur- vival after hospital admission was 138 days for treated patients and 152 days for controls, with median durations of disease of 6.3 months and 6.8 months. The other study 17 reported a transient improvement in wakefulness and cognition in three of four treated patients, but, in two of these patients, myoclonus (involuntary muscle movement) increased. Median survival after the start of clinical care was 45 days for the treatment group and 28 days for the control group, the authors stating that this did not differ significantly between the two groups. Median duration of disease was 7 months and 3 months. However, a significant difference in time from onset of disease to start of hospital care between the groups suggests underlying differences, which makes comparison of outcomes unreliable.
In three case reports, no effect was detected. [20] [21] [22] The other three studies reported benefits. 18, 19, 23 One individual was reported as having improved from being mute and immobile to being able to sit in a wheelchair and capable of limited communication, 18 but was later reported by another author to have died of sepsis at 9 months post treatment. 19 The same article 19 describes the treatment of two other patients, one of whom had a transient improvement in mental and physical symptoms, but who died of bronchopneumonia 3.5 months later (with autopsy confirmation of CJD). Progressive improvement was noted for the other patient who was alive at the time of the report, 30 months after starting treatment, and reportedly still alive after a few years, 23 the diagnosis of CJD not being pathologically confirmed. The third article 23 describes some clinical improvement in a patient in whom rigidity disappeared, incontinence cleared, and who sometimes became more rational and communicative, followed by a long period of stability. This patient died 4.5 years after treatment began, owing to inhalation of vomit while suffering from gastroenteritis, and CJD was confirmed pathologically. Vidarabine. One case report 24 describes the use of vidarabine at 15 mg/kg/day to treat three patients with unspecified CJD. The author describes the treatment as being of benefit, having observed a favorable palliative response in two out of three patients. For the woman whose case is presented more fully, a transient improvement was reported during which all neurologic symptoms improved and involuntary movement ceased. Repeated cycles of treatment and response were observed. The patient died 9 months after treatment started and 12 months after diagnosis. Toxicity was not commented on.
Antimalarial drugs. Quinacrine. One comparative study 25 and 10 case reports/series, [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] including a total of 82 patients treated with quinacrine (mepacrine hydrochloride), were published between 2002 and 2006. In all but one of these the drug was given at a planned dose of 300 mg/day, with provision for dose reduction and modification if required.
A prospective study of 30 sCJD and two vCJD patients 25 evaluated progression every 30 days based on a Rankin disability score, and compared survival with 125 concurrent untreated patients. Measurement was disrupted before first evaluation in 14 patients owing to death, side effects, or severe clinical condition. Disease remained stable in 10 cases and worsened in 6 (2 patients were not accounted for). There was no significant difference in mean survival following treatment, which was 8.8 months for the treated sCJD patients compared to 7.0 months for control group patients. Furthermore, it was noted that the apparent difference could be due to imbalances in genotypes, such that the treated group included more patients expected to survive longer, irrespective of any treatment. Comparisons of autopsied brain tissue from patients, treated for more than 30 days, with tissue from historical controls found that the patterns of PrP deposit in the brains of treated patients could not be distinguished from those of untreated cases matched by codon 129 polymorphism (thought to modify susceptibility to and phenotype of prion disease). Observed side effects were transaminase elevation (6), cutaneous eruption (2), digestive intolerance (1), and leukopenia (1) .
Of the 10 case reports/series, one 30 reports minimal information, one does not comment on the effect of quinacrine, 29 and four 27,28,31,33 did not detect any effect. Three studies including four, 26 one, 32 and three 35 patients report a benefit. The first reports a transient clinical improvement of 2 to 8 weeks during which patients showed increased responsiveness, restoration of some cognitive function, and reduced myoclonus. The second describes transient benefit over 3 weeks during which the patient regained both limb and pursuit eye movement, but treatment had to be stopped owing to liver dysfunction. The third also reports a transient benefit in all patients although treatment had to be discontinued in the patient receiving higher dose quinacrine because of liver toxicity. Quinacrine toxicity is also noted in a further six reports as liver dysfunction and yellow pigmentation, 26, 28 dose-modifying liver toxicity and rash, 30 liver toxicity and bone mar-row aplasia, 31 cytolytic hepatitis, 27 and psychosis and psoriasis. 34 The final study 34 reported continued deterioration of two patients who had treatment withdrawn due to lack of efficacy and toxicity.
Anticoagulant drugs. Pentosan polysulfate. Three case reports each describe the treatment, with intraventricular pentosan polysulfate (PPS), of single vCJD patients. The first 36 describes a woman treated with PPS and the authors state that there was no definite clinical benefit noted, although the patient's family did note some improvement. The patient died 5 months after the initiation of treatment, 16 months after onset of symptoms. The second 37 describes a young man with vCJD treated with PPS. The drug did not appear to stop disease progression which continued slowly over the next 18 months. This was followed by an apparent stabilization of clinical symptoms, although the authors state that this may reflect reduced sensitivity for detection of change. The patient was reported as still alive 31 months after treatment and 51 months after onset of symptoms. The authors also state that PPS appeared to be safe and well tolerated. The third report 38 describes another young man with vCJD treated with PPS and reports some evidence of clinical improvement including the ability to fix his eyes on people, obey simple commands, and make verbalization attempts in response to stimuli. His sleep/wake cycle and reflex swallow were restored and myoclonus was reduced. He also gained weight, but brain atrophy, as measured by repeated CT scans, continued. The patient was reported alive 37 months after the onset of symptoms and 18 months after the start of treatment with no reported pentosan toxicity. A further article 39 describes this same individual as alive at 48 months after the start of treatment, along with another 23 patients treated with the same drug. Only brief information is presented for these 23 patients. Initial improvement followed by slow progression was observed in two, initial stabilization of disease followed by slow progression in one, stable disease in five, slow progression in four, and continuous deterioration in six patients. The effect of treatment was not reported for the remaining five patients. The authors also noted that long-term administration of PPS appeared to be reasonably safe and that the maximum tolerated dose of PPS had not yet been reached.
Antifungal drugs. Amphotericin. One report 40 describes two unspecified CJD patients treated with amphotericin at 0.25-1.0 mg/day. No effect of treatment was detected on clinical symptoms or disease progression. Durations of disease were 4 and 8 months. Toxicity was stated as none for one patient and was not commented on for the other.
Biologic response modifiers. Interferon. One report 41 describes treatment with human leukocytic interferon in two patients, one with sCJD and one with iPD. No change was observed in the patients' conditions. One died 7 months after treatment started and had a disease duration of 15 months. Date of death is not given for the other who had duration of disease greater than 21 months. Toxicity was not commented on.
Antidepressant drugs. Clomipramine and venlafaxine.
One article 42 reports a single case of vCJD treated with clomipramine at 125 mg/day for 3 weeks followed by venlafaxine at 200 mg/day for 7 weeks. No effect of either drug was noted in the patient, who died 8 months after treatment started and 14 months after diagnosis. Toxicity was not commented on.
Analgesic drugs. Flupirtine. A double-blind randomized controlled trial of 26 sCJD and two iPD patients compared flupirtine with a matched placebo. 43 The primary outcome was the difference between a single baseline and best score under treatment on the cognitive part of the ADAS-cog assessment score. The authors report a benefit of the drug in terms of cognitive function, with flupirtine patients showing less deterioration in the dementia tests (reported one-sided p ϭ 0.02). This was supported by similar findings across a number of other clinical questionnaires and also by assessment by carers. No difference in survival was detected (log rank p ϭ 0.19). Median survival was 107 days on flupirtine and 106 days on placebo. Toxicities reported in patients receiving flupirtine were urticaria (1), gastrointestinal bleeding (1), and muscle weakness (1) . A conference abstract revealed that a further eight patients had been treated with a combination of flupirtine and dapsone 44 according to the same protocol. Correspondence with the author confirmed that these patients had not been randomized and were treated outside the trial. No results of cognitive testing of these patients were available (M. Otto, personal communication).
Anticonvulsant drugs. Levetiracetam. One report 45 describes the use of levetiracetam given to a patient with unspecified CJD at 1,000 -2,000 mg/day for myoclonus control. A marked reduction in myoclonus was observed and the patient was alive at the time of the report. Toxicity was stated as none.
Topiramate/phenytoin. One case report 46 describes the use of phenytoin at a dose of 300 mg/ day then topiramate at 100 -200 mg/day. It notes a benefit when the topiramate was started. Myoclonus and rigidity were decreased and movement and communication improved in this patient, who was alive at the time of the report, 1 month after treatment. However, contact with the author revealed that they believe the patient was misdiagnosed, did not have CJD, and that the point of their report was differential diagnosis. However, this was not immediately clear from reading the article. The patient died about 7 months after treatment began and no autopsy was performed (A. Floel, personal communication). Antioxidants. One report 47 describes the treatment of a case of CJD that was probably iatrogenic in origin, with a number of antioxidants and mineral and vitamin supplements administered by the patient's family. A benefit of treatment was reported with clinical improvement in responsiveness, myoclonus, apnea, and rigidity. The patient died 19 months after the start of treatment with disease duration of 22 months. Although we did not systematically search for these, two ongoing treatment studies were also identified during Internet searches. The Haute Autorité de Santé Web site (www.has-sante.fr) refers to a French study (Vighetto et al.) evaluating the efficacy and tolerability of PPS in patients with CJD. The University of Ulm Web site (www. uniklinik-ulm.de/struktur/kliniken/neurologie) contains information about a current German study (Otto et al.) evaluating the treatment of patients with CJD with Simvastatin. DISCUSSION Owing to lack of formal evaluation of drug effectiveness, we systematically reviewed all clinical reports of human prion disease and considered a total of 173 studies involving over 9,000 patients. Observational data from patient series revealed a wide range of disease duration. For example, for sCJD the median of reported average time from onset of symptoms to death is 6 months, but individual disease durations range from 1 month to 11 years. Undoubtedly a more reliable way to evaluate information on onset, course, and duration of disease would be to pool standardized data from national surveillance programs. An article 48 collating information from several of these to investigate prognostic factors reported comparable average age at onset and duration of disease to those found here (it did not present data by country, or by mutation). Continued collaboration between these programs to obtain robust baseline information will be extremely valuable.
The effects of nine drugs (amphotericin, clomipramine/venlafaxine, interferon, levetiracetam, topiramate/phenytoin, vidarabine, and antioxidants and vitamin supplements) 24, [40] [41] [42] [45] [46] [47] have been reported only in single studies of three or fewer patients and one drug (acyclovir) has had two published individual case reports. 13 Consequently it is impossible to draw any conclusions as to the effectiveness or ineffectiveness of these agents.
The effects of four drugs have been studied in more detail. Amantadine was given to a total of 24 patients in two questionable comparative studies 16, 17 and six case reports, [18] [19] [20] [21] [22] [23] conducted mainly during the 1970s. The various authors of these reports drew different conclusions from their observations, four reporting some benefit [17] [18] [19] 23 and the other four reporting that no effect of treatment had been observed. 16, [20] [21] [22] Furthermore, in articles reporting patient series we found brief information that other patients in the United Kingdom, 49 Argentina, 14 and Finland 15 had been treated unsuccessfully with this drug. The publicly available evidence on PPS is restricted to detailed information on three published cases [36] [37] [38] and brief tabulated descriptions of a further 23 treated patients. 39 Mixed results have been observed. Of these patients two 37, 38 have now survived longer than the range observed in surveillance data or patient series but we must be careful not to overinterpret these observations as those patients may be exceptional cases. However, it highlights the need for continued monitoring and reporting of all treated patients. While there is more informa-tion available on quinacrine, effects having been reported for a total of 82 patients, results have been mixed and toxicity noted. A comparative study of 32 patients 25 failed to find any obvious improvement in clinical status and no significant difference in survival between the treated and control group of patients. Of the case studies/ series, one presented minimal information, 30 one did not comment on treatment effect, 29 three report a benefit of treatment, 26, 32, 35 four report no effect, 27, 28, 31, 33 and one concluded that it was harmful. 34 Toxicity, particularly liver dysfunction, is reported in 10 of the studies. [25] [26] [27] [28] [30] [31] [32] [33] [34] [35] The only reliable reported randomized trial 43 suggests flupirtine may slow cognitive decline. However, the number of patients included in the study was small and it remains possible that these were chance findings. Importantly, this trial has also demonstrated proof of concept, that it is indeed possible to carry out randomized controlled trials in human prion disease, and should lead the way for future studies.
Many reports included in the review were flawed or poorly described, and must be interpreted with caution. Case reports form a substantial part of the review of treatment. As well as the often subjective way these are reported, publication bias 50 may be a problem. While there may be enthusiasm to write up a case with a perceived positive outcome, there may be less incentive to publish those where an intervention has failed to alleviate symptoms or alter the course of disease. For example, one patient series 51 refers to 29 patients who had been treated with amantadine, only one of whom responded to treatment. This patient had been published separately 23 whereas the remaining 28 patients, who experienced no benefit, were not. In many studies, it was not clear whether observations were prospective or retrospective. If planned in advance, case selection should have been made according to specified criteria and clinical assessment done in a structured way. However, if studies considered prior patients, then both patient selection and outcome could have been subject to bias. Studies were also not clear on whether control patients were concurrent or historical. If the latter, then influences other than treatment could be responsible for any observed differences. A high proportion of evidence is from abstracts, letters, and short reports where it is often difficult to discern whether lack of information implies, for example, that a particular side effect was not observed or simply that it was not reported. Nonetheless, we believe that, within the constraints of the ap-proach, this systematic review represents a comprehensive and accurate summary of the current published literature on human prion disease.
For over 30 years patients with prion disease have been treated on an ad hoc, largely inadequately controlled basis. As our review reveals, this poorly coordinated approach has resulted in little progress in defining useful treatments or the best way of evaluating potential treatments. If we are to make advances in the treatment of human prion disease this must be changed, and the treatment and disease course of current and future patients evaluated within a structured framework. With the exception of the two PPS patients we have already discussed, based on the published information available at the time of this review, survival of treated patients has been within the ranges of those reported in surveillance datasets and untreated patient series.
The anticipated benefits of current drugs, or those in development, seem unlikely to be dramatic and consequently easily obscured by uncontrolled biases. Future evaluations should therefore, wherever possible, be comparative and made within the context of randomized controlled trials.
Large numbers of participants are required to identify modest effects (beneficial or harmful) with reliability, and given that fortunately, at present, prion disease remains rare, robust estimation of effectiveness requires national and international collaboration. This could be achieved by future collaborative clinical trials or by designing similar trials and agreeing to pool these in a prospective meta-analysis. Although it will be important to take account of cultural, ethical, and care differences between countries, an international "joined-up" approach to monitoring and treatment evaluation is our best hope of improving the outlook for patients with these devastating diseases.
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